Across TCGA pan-cancer cohorts, TRAJ20 RNA differs between tumor and matched normal tissue in 1 of 18 cancer types tested, making tumor–normal expression one of TRAJ20’s most consistent transcriptional readouts.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TRAJ20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TRAJ20 is over-expressed in tumor.
KIRC are the cancer types where TRAJ20 tumor–normal differential expression is most reproducible.